Compile Data Set for Download or QSAR
Report error Found 105 Enz. Inhib. hit(s) with all data for entry = 12155
TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682994(US20240208986, Compound 2-25 | (2S,5S)-7-fluoro-4-...)
Affinity DataIC50: 10nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682995(US20240208986, Compound 2-26 | 1-[(2S,5S)-7,9-difl...)
Affinity DataIC50: 12nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM683004(US20240208986, Compound 2-35 | ((2S,5S)-7,9-difluo...)
Affinity DataIC50: 12nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682950(US20240208986, Compound 1-41 | (4- (difluoromethyl...)
Affinity DataIC50: 13nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682983(US20240208986, Compound 2-14 | (bicyclo[2.2.1]hept...)
Affinity DataIC50: 15nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682996(US20240208986, Compound 2-27 | 4-[(2S,5S)-7,9-difl...)
Affinity DataIC50: 16nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682953(US20240208986, Compound 1-44 | [(2S,5S)-2,3-dihydr...)
Affinity DataIC50: 17nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682952(US20240208986, Compound 1-43 | (bicyclo[2.2.2]octa...)
Affinity DataIC50: 18nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682988(US20240208986, Compound 2-19 | (2S,5S)-4-(3,3-difl...)
Affinity DataIC50: 18nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM683005(US20240208986, Compound 2-36 | 4-((2S,5S)-7,9-difl...)
Affinity DataIC50: 19nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682981(US20240208986, Compound 2-12 | 3,3-difluoro-1-[(2S...)
Affinity DataIC50: 20nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682977(US20240208986, Compound 2-8 | 3,3-difluoro-1-[(2S,...)
Affinity DataIC50: 20nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682931(US20240208986, Compound 1-22 | 1-[(2S,5S)-2,3-dihy...)
Affinity DataIC50: 21nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682937(US20240208986, Compound 1-28 | 2-cyclopropyl-1-[(2...)
Affinity DataIC50: 22nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682982(US20240208986, Compound 2-13 | 3,3-difluoro-1-[(2S...)
Affinity DataIC50: 23nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682949(US20240208986, Compound 1-40 | ((2S,5S)-2,3-dihydr...)
Affinity DataIC50: 23nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682984(US20240208986, Compound 2-15 | (bicyclo[2.2.1]hept...)
Affinity DataIC50: 24nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682976(US20240208986, Compound 2-7 | 3,3-difluoro-1-[(2S,...)
Affinity DataIC50: 25nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682987(US20240208986, Compound 2-18 | 4-[(2S,5S)-9-fluoro...)
Affinity DataIC50: 25nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682980(US20240208986, Compound 2-11 | (2S,5S)-4-(3,3-difl...)
Affinity DataIC50: 26nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM683002(US20240208986, Compound 2-33 | ((2S,5S)-8-chloro-2...)
Affinity DataIC50: 26nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM683003(US20240208986, Compound 2-34 | 2-(4-((2S,5S)-7,9-d...)
Affinity DataIC50: 27nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682979(US20240208986, Compound 2-10 | [(2S,5S)-9-fluoro-2...)
Affinity DataIC50: 30nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682993(US20240208986, Compound 2-24 | 1-[(2S,5S)-9-chloro...)
Affinity DataIC50: 30nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682913(US20240208986, Compound 1-4 | bicyclo[2.2.1]heptan...)
Affinity DataIC50: 33nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682974(US20240208986, Compound 2-5 | 1-[(2S,5S)-7-fluoro-...)
Affinity DataIC50: 34nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682985(US20240208986, Compound 2-16 | 1-((2S,5S)-8-chloro...)
Affinity DataIC50: 35nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682990(US20240208986, Compound 2-21 | 1-[(2S,5S)-8-chloro...)
Affinity DataIC50: 37nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM683001(US20240208986, Compound 2-32 | ((2S,5S)-7-chloro-2...)
Affinity DataIC50: 39nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682914(US20240208986, Compound 1-5 | ((2S,5S)-2,3-dihydro...)
Affinity DataIC50: 42nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682915(US20240208986, Compound 1-6 | ((2S,5S)-2,3-dihydro...)
Affinity DataIC50: 43nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682964(US20240208986, Compound 1-55 | methyl 4-[(2S,5S)-2...)
Affinity DataIC50: 43nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682975(US20240208986, Compound 2-6 | 1-[(2S,5S)-9-fluoro-...)
Affinity DataIC50: 43nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682926(US20240208986, Compound 1-17 | 1-[(2S,5S)-2,3-dihy...)
Affinity DataIC50: 47nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682908(US20240208986, Compound 1-1 | 1-((2S,5S)-2,3-dihyd...)
Affinity DataIC50: 48nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682992(US20240208986, Compound 2-23 | 4-((2S,5S)-8-chloro...)
Affinity DataIC50: 49nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682986(US20240208986, Compound 2-17 | 4-[(2S,5S)-7-fluoro...)
Affinity DataIC50: 51nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682989(US20240208986, Compound 2-20 | 1-[(2S,5S)-9-chloro...)
Affinity DataIC50: 52nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682998(US20240208986, Compound 2-29 | 3-((2S,5S)-7-fluoro...)
Affinity DataIC50: 55nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682966(US20240208986, Compound 1-57 | 4-[(2S,5S)-2,3-dihy...)
Affinity DataIC50: 56nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682938(US20240208986, Compound 1-29 | [1- (difluoromethyl...)
Affinity DataIC50: 58nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682935(US20240208986, Compound 1-26 | [(2S,5S)-2,3-dihydr...)
Affinity DataIC50: 60nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682973(US20240208986, Compound 2-4 | 1-[(2S,5S)-7,9-diflu...)
Affinity DataIC50: 60nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682909(US20240208986, Compound 1-2 | 1-((2S,5S)-2,3-dihyd...)
Affinity DataIC50: 61nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682970(US20240208986, Compound 2-1 | 1-[(2S,5S)-7-chloro-...)
Affinity DataIC50: 61nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682929(US20240208986, Compound 1-20 | [(R and S)-2,2-dich...)
Affinity DataIC50: 62nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682978(US20240208986, Compound 2-9 | [(2S,5S)-7-fluoro-2,...)
Affinity DataIC50: 63nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682933(US20240208986, Compound 1-24 | 1-[(2S,5S)-2,3-dihy...)
Affinity DataIC50: 69nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682927(US20240208986, Compound 1-18 | 1-[(2S,5S)-2,3-dihy...)
Affinity DataIC50: 73nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM682999(US20240208986, Compound 2-30 | 3-((2S,5S)-9-fluoro...)
Affinity DataIC50: 75nMAssay Description:In this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution; top compound concentration of 100000 nM) tit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/4/2024
Entry Details
US Patent

Displayed 1 to 50 (of 105 total ) | Next | Last >>
Jump to: